Found: 27
Select item for more details and to access through your institution.
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1455979
- By:
- Publication type:
- Article
A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 7, p. 1575, doi. 10.1007/s40121-024-00992-5
- By:
- Publication type:
- Article
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 10, p. N.PAG, doi. 10.3390/pharmaceutics14102159
- By:
- Publication type:
- Article
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231183680
- By:
- Publication type:
- Article
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 9, p. 3573, doi. 10.1007/s00277-024-05912-8
- By:
- Publication type:
- Article
Oral docetaxel plus encequidar – a phase 1 clinical trial.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 94, n. 3, p. 475, doi. 10.1007/s00280-024-04674-4
- By:
- Publication type:
- Article
Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 6, p. 1493, doi. 10.1111/bcp.16043
- By:
- Publication type:
- Article
Novel long‐acting ropeginterferon alfa‐2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 5, p. 2396, doi. 10.1111/bcp.15176
- By:
- Publication type:
- Article
A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer.
- Published in:
- Cancers, 2024, v. 16, n. 17, p. 3052, doi. 10.3390/cancers16173052
- By:
- Publication type:
- Article
Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 4, p. 391, doi. 10.1007/s40261-021-01026-5
- By:
- Publication type:
- Article
Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.
- Published in:
- Viruses (1999-4915), 2022, v. 14, n. 6, p. N.PAG, doi. 10.3390/v14061128
- By:
- Publication type:
- Article
A Sensitive Assay for Unbound Docetaxel Using Ultrafiltration plus HPLC-MS and Its Application to a Clinical Study.
- Published in:
- Pharmaceutics, 2024, v. 16, n. 5, p. 602, doi. 10.3390/pharmaceutics16050602
- By:
- Publication type:
- Article
Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b.
- Published in:
- International Journal of Hematology, 2024, v. 120, n. 2, p. 151, doi. 10.1007/s12185-024-03804-1
- By:
- Publication type:
- Article
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
- Published in:
- International Journal of Hematology, 2022, v. 116, n. 2, p. 215, doi. 10.1007/s12185-022-03341-9
- By:
- Publication type:
- Article
Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
- Published in:
- 2022
- By:
- Publication type:
- corrected article
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2024, v. 51, n. 4, p. 335, doi. 10.1007/s10928-024-09913-y
- By:
- Publication type:
- Article
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
- Published in:
- Experimental Hematology & Oncology, 2023, v. 12, n. 1, p. 1, doi. 10.1186/s40164-023-00415-0
- By:
- Publication type:
- Article
An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1173467
- By:
- Publication type:
- Article
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1109866
- By:
- Publication type:
- Article
Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 2, p. 847, doi. 10.1007/s12325-023-02715-7
- By:
- Publication type:
- Article
Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 2, p. 910, doi. 10.1007/s12325-021-01998-y
- By:
- Publication type:
- Article
Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 9, p. 4756, doi. 10.1007/s12325-021-01863-y
- By:
- Publication type:
- Article
Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 1, p. 433, doi. 10.3390/ijms25010433
- By:
- Publication type:
- Article
A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C.
- Published in:
- JGH Open, 2022, v. 6, n. 11, p. 782, doi. 10.1002/jgh3.12825
- By:
- Publication type:
- Article
Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.
- Published in:
- JGH Open, 2021, v. 5, n. 8, p. 929, doi. 10.1002/jgh3.12613
- By:
- Publication type:
- Article
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1455979
- By:
- Publication type:
- Article